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Nav1.5 biologyThe aim of this mini-review is to draw together the main concepts and ﬁndings that have emerged from recent
studies of the cardiac channel protein Nav1.5. This complex protein is encoded by the SCN5A gene that, in its mu-
tated form, is implicated in various diseases, particularly channelopathies, speciﬁcally at cardiac tissue level. Here
we describe the structural, and functional aspects of Nav1.5 including post-translational modiﬁcations in normal
conditions, and the main human channelopathies in which this protein may be the cause or trigger. Lastly, we
also brieﬂy discuss interacting proteins that are relevant for these channel functions in normal and disease
conditions.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The voltage-gated sodium channels are large transmembrane pro-
teins responsible for the initial and rapid phase of the action potential
in most electrically excitable cells [1]. All sodium channels consist of 2
different subunits: the α-subunit that constitutes the voltage-gated
sodium-selective aqueous pore, and the β-subunits (one or two) that
are responsible for channel regulation and localization [2]. Nav1.5 is
the voltage-gated sodium channel isoform expressed speciﬁcally in car-
diac tissue [1]. It is distributed in atrial and ventricular myocytes and
Purkinje ﬁbers. This channel is an essential player in cardiac action po-
tential initiation and subsequent propagation through the heart [3].
Given the key role played by Nav1.5 in cardiac electrical excitability
and stability, mutations that alter channel function are involved in the
pathogenesis of arrhythmic, and also in structural, inherited genetic
disorders. This mini-review provides an overview and update of the
human cardiac sodium channel protein Nav1.5 and related diseases.
2. Structure of the voltage-gated sodium channel
The human cardiac sodium channel (Nav1.5) is a member of
the voltage-dependent family of Na channels. This family consists ofzate, Via Gaetano Salvatore 486,
. This is an open access article under9 members (Nav1.1–1.9), encoded by 9 genes (SCN1–5A, and SCN8–
11A); the amino acid sequences of the proteins are more than 50%
homologous [4]. These channels consist of the heteromeric assembly
of an α-subunit (the pore-forming component) which is functionally
modulated by its association with two ancillary β-subunits. Currently
5 β-subunits, encoded by 4 genes (SCN1B–SCN4B), have been identiﬁed
in mammals (β1–β4 and β1B) [5]. The α-subunit is sufﬁcient to allow
sodium ions to ﬂow through the cell membrane and thus to generate
the sodium currents (INa). β-subunits are unable to generate sodium
currents independently of theα-subunit, and they probably serve to fa-
cilitate sodium channelmigration toward the cellmembrane by directly
interacting with the α-subunit [4].
Nav1.5 is encoded by the SCN5A gene that is located on chromosome
3p21 and consists of 28 exons [6]. The Nav1.5 α-subunit is a large inte-
gral membrane protein (227 kDa) consisting of 2016 amino acids orga-
nized in four homologous transmembrane domains, designated D1–D4
(D1, aa 127–416; D2, aa 712–939; D3, aa 1201–1470; D4, aa 1524–
1772) (Fig. 1A). These 4 domains assemble in a speciﬁc 3D-structure
to create an aqueous pore, with alternation of positive charges, which
connects the cytoplasmic compartment of the cell to the extracellular
medium (Fig. 1B) [4]. This 3D organization exposes speciﬁc binding
sites and facilitates ion movement. Each of the 4 domains contains 6
α-helical trans-membrane segments (S1–S6) and is connected to the
adjacent domain by interdomain linker loops (ID1–2, aa 416–711;
ID2–3, aa 940–1200; ID3–4, 1471–1523) (Fig. 1A). The S4 segment
(voltage sensor) of each domain contains positively charged aminothe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. (A) Schematic representation of the Nav1.5 cardiac sodium channel. IFM is the fast inactivation region represented by isoleucine, phenylalanine and methionine, the gray circle
represents the β-subunit interaction region; VSD is the Voltage Sensing Domain; ID1–2, ID2–3, ID3–4 are the interdomain linkers. On the extreme right is a schematic representation
of the β-subunit. (B) Schematic tridimensional representation of Nav1.5. The blue, red, yellow and green blocks represent domains 1, 2, 3 and 4, respectively. The gray circles represent
the β-subunits. The light blue circle represents the aqueous pore.
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ing voltage variation (depolarization), causes channel opening [4].
The P-loop is a highly conserved pore-forming region between
S5 and S6 of each domain. Being inserted in the phospholipid bilayer,
the P-loop creates the hole through which sodium ions cross the cell
membrane (Fig. 1A). This region is important in determining sodium
ion selectivity and for the conductance/permeation properties especial-
ly thanks to the presence of a selectivity ﬁlter constituted by aspartic
and glutamic acid, lysine and alanine residues (the DEKA ring) [7]. In
fact, a single amino acid variation in the P-loop can alter ion selectivity
[8].
The region of fast inactivation regulation is located between ID3 and
ID4 (see Fig. 1A), whereas the intracellular C-terminal tail (aa 1772–
2016) is a protein-interacting region. The correct location of Nav1.5 at
the cell membrane is mediated by several cell-trafﬁcking proteins
including the β-subunits (hβ1) that also play a role in the regulation
of the activation, inactivation and recovery from inactivation of the
cardiac sodium channel [5].3. Function and voltage-dependent activation of Nav1.5
Within cardiac tissue, the Nav1.5 protein generates and propagates
the cardiac action potential (CAP) that is responsible for normal heart
contraction. The CAP consists of 5 phases lasting about 200–300 milli-
seconds overall:, rapid depolarization, which is mediated by a rapid
inﬂux of sodium ions (induced by Nav1.5 opening, INa) (phase 0);
early repolarization (phase 1), which is caused by the transient outwardpotassium current (IKto) that induces a rapid and brief repolarization of
cell membrane; plateau (phase 2), which is maintained by the simulta-
neous exit of potassium ions (IKur) and the entry of calcium ions (ICaL);
ﬁnal repolarization (phase 3), which restores the resting potential.
Final repolarization results from outward potassium currents: rapid
(IKr) and slow (IKs); and phase 4 the resting phase (about −85 mV).
In the ventricules, this phase is due to IK1 current (Kir2.1).
The Nav1.5 channel generates phase 0 — that triggers the cardiac
CAP. Once a cell is electrically stimulated by a current from adjacent
cells, the cardiac sodium channels open thereby causing a rapid inﬂux
of sodium ions into the cell. This movement of ions induces rapid depo-
larization of the cell membrane from the resting potential (about
−85 mV, phase 4) to a positive voltage (about +20 to +45 mV,
phase 0). The ﬂow of sodium ions through the cell membrane, respon-
sible for the phase 0 trigger, is induced by the transition of the channel
from a closed state (at the resting potential,−85mV) to an open state.
Speciﬁcally, the S4 segmentmoves outwardwith respect the S1–S2 and
S3 segments; it rotates around its own axis and ﬁnally tilts with respect
to the S4–S5 linker loop. These changes drive the movement of the
S4–S5 linker loop that causes the entire S1–S4 block (called voltage
sensing domain, VSD, Fig. 1A) rotation and enables sodium ions to
enter the cell [9].4. Fast inactivation of Nav1.5
The ion ﬂow across the cell membrane stops when the channel
closes. In fact, when depolarization is maintained, the channel enters
1504 N. Detta et al. / Biochimica et Biophysica Acta 1854 (2015) 1502–1509into a closed non-conducting state [10]. When the membrane is
depolarized, the cardiac sodium channel closes thanks to the inactiva-
tion process. Nav1.5 is inactivated by two physically distinct inactivation
processes: fast inactivation and slow inactivation [11]. The fast inactiva-
tion process is coupled to the activation process. In fact, it starts as
activation proceeds [12]. This rapid (milliseconds) mechanism of clo-
sure of Nav1.5 is driven by the ID3–4. Speciﬁcally, a highly conserved
amino acid triad, consisting in isoleucine–phenylalanine–methionine
(IFM; residues 1485–1487, Fig. 1A), is directly and critically involved
in this rapid inactivation. In fact, mutation of the IFM triad with three
glutamine residues (IFM→ QQQ) abolishes channel inactivation [13].
The 54 amino acid residues of the ID3–4 linker-loop region are probably
involved in modulation of inactivation properties. In fact, mutations/
deletions in this loop generally negatively affect Nav1.5 inactivation
thereby leading to cardiac channelopathies (i.e., Brugada syndrome
[BrS] and LongQT syndrome [LQTS]) [14]. Fast inactivation of Nav1.5 oc-
curs via a “ball & chain” mechanism where the “ball”, which occludes
the pore, is represented by the interdomain linker loop ID3–4. Thus,
ID3–4 interrupts the ﬂow of ions through the channel.
Mutations in the cytosolic interdomain linker loop ID1–2 also accel-
erate the fast inactivation process, although it is not known if the control
of the fast inactivation kinetics mediated by ID1–2 is induced by direct
interaction of ID1–2 with the “standard” fast inactivation apparatus
(namely ID3–4) or by allosteric modulation of the gate kinetics [15].
Also the C-terminal tail of Nav1.5, by interacting directly or indirectly
with the ID3–4, may be involved in modulation of channel inactivation
(Fig. 1A) [16].5. Slow inactivation of Nav1.5
Slow inactivation of Nav1.5 differs greatly from fast inactivation. In
fact, unlike fast inactivation, this process is not coupled to activation, it
does not start during activation progression, and can be sustained for
as long as a few seconds [17]. The sodium channel enters this stable
non-conducting state when channel activation (depolarization ofmem-
brane) is prolonged. The slow inactivation mechanism is induced by
conformational modiﬁcations that directly involve the pore structure.
The rearrangement of the pore, which blocks sodium ion transport
through the membrane, is driven by 3 extracellular domains: the
trans-membrane segment S4/D4, the loop between S5–S6/D2 (P-loop/
D2) and segment S6/D2. The conformational changes mediated by
these regions of the protein induce channel inactivation, whereas the
entrance of the pore is unaffected [11]. Mutations in the P-loop regions
of Nav1.5 (C373F in P-loop/D1 and H880Q in P-loop/D2) destabilize the
slow inactivation states — a ﬁnding that implicates also P-loop/D1 in
slow inactivation modulation, and conﬁrms the role of P-loop/D2 in
slow inactivation of the channel [18].6. Post-translation modiﬁcations
6.1. Glycosylation
Nav1.5 undergoes several post-translational modiﬁcations that
modulate its functional behavior. These modiﬁcations can modulate
both the channel kinetic and targeting of the protein toward the cell
membrane.
The sodium channel is a heavily glycosylated protein. Both
channel activation and channel inactivation are regulated by this post-
translational modiﬁcation. Studies of the role of sialylation in ST3Gal4
(sialyltransferase)-deﬁcient mice demonstrated that the lack of this
post-translational modiﬁcation signiﬁcantly shifts activation/inactivation
to more positive potentials (depolarizing shift) and, in addition, the
recovery from fast inactivation is accelerated, whereas targeting of
Nav1.5 toward the cell membrane is not affected [19].6.2. Phosphorylation
Phosphorylation can alter both trafﬁcking and gating of the cardiac
sodium channel. In fact, direct phosphorylation of Nav1.5 by protein
kinase A (PKA) increases channel density on the cell surface thereby fa-
cilitating targeting of the protein probably by masking the endothelial
reticulum retention signals [20]. Mutations affecting the PKA phosphor-
ylation consensus site of Nav1.5 induce the loss of PKA-mediated phos-
phorylation and results in dysregulation of trafﬁcking and signaling
(R526H associated to Brugada syndrome) [21]. On the contrary, the
phosphorylation of Nav1.5 mediated by protein kinase C (PKC) induces
a reduction of INa amplitude. This effect is due to distribution of the
sodium channel away from the plasma membrane and to modiﬁcation
of the intracellular trafﬁcking rate [22]. Moreover, Nav1.5 can be phos-
phorylated by CaMKII. Particularly, S571phosphorylation reduces chan-
nel availability and enhances persistent current thereby increasing the
susceptibility to after depolarizations [23]. S571 and the proximate
residues are a critical site for regulation of channel function. In fact, in-
creased levels of S571 phosphorylation have been found in acquired
cardiac diseases and,moreover, mutations in S571 neighboring residues
(i.e. A572D and Q573E) alter the CaMKII-inducedmodulation of Nav1.5,
and results in altered susceptibility to pro-arrhythmic phenotypes [23,
24]. In addition, CaMKII-induced phosphorylation of pS516 and pS594
alter channel availability. Indeed, it shifts Na channel availability to a
more negative potential and increases the accumulation of the channel
in an intermediate inactivated state [25]. A mass spectrometry study of
the cardiac sodium channel of ventricular cardiomyocytes from adult
mice, showed that all the phosphorylated siteswere located in the intra-
cellular interdomain linkers ID1–2 (pS457, pS460, pS483, pS484, pS497,
pS510, pS524 and/or pS525, pS571, pS664, pS667); except some sites
that were located in the N-terminal tail (pS36, pT38, S39 and/or pS42)
[26].
6.3. Ubiquitination
Ubiquitination of Nav1.5 also alters the trafﬁcking of the protein to
the cell membrane. This post-translational modiﬁcation is implicated
in the degradation and/or internalization of membrane proteins, as
well as in such non-proteolytic effects as the control of DNA-damage
and/or cell signaling [27]. The cardiac sodium channel has a conserved
PY-motif in the C-terminal tail that is a binding site for ubiquitin-
protein ligases (Nedd4/Nedd4-like). Nedd4-2-mediated ubiquitination
of the protein (mono- or oligo-ubiquitination) reduces the density
of Nav1.5 on the cell surface probably by accelerating channel internal-
ization. This modiﬁcation does not affect channel kinetics (voltage-
dependent activation and inactivation) [28]. There is evidence that
Nav1.5 is ubiquitinated not only by the Nedd4-2 protein, but also by
other ubiquitin-protein ligases, albeit to a lesser extent (Nedd4-1 and
WWP2). WWP2-mediated but not Nedd4-1-mediated ubiquitination
decreases channel density at the cell membrane (b30%) [29].
6.4. Other post-transcriptional modiﬁcations
The Nav1.5 protein can also undergo such post-translational
modiﬁcations as S-nitrosylation. This modiﬁcation of the channel
protein causes the persistence of the late sodium current in
cardiomyocytes [30]. A novel Nav1.5 post-transcriptional modiﬁca-
tion, i.e. arginine methylation (ArgMe), has been identiﬁed in argi-
nine residues in the intracellular interdomain linker ID1–2 [31].
This Nav1.5 modiﬁcation results from protein arginine methyltrans-
ferases (PRMT-1, -3, -5) and leads to a mono- or dimethylated
arginine [32]. The ArgMe modiﬁcation improves the cell surface mi-
gration of Nav1.5. In fact, current density was increased in cells ex-
pressing Nav1.5 together with PRMT-3 or PRMT-5, whereas channel
kinetics (activation, inactivation, and recovery from inactivation)
were unchanged. These ﬁndings suggest that the increased current
Table 1
Nav1.5-interacting proteins, relative binding domains and functions affected [34].
Protein Mass
(kDa)
Nav1.5 interacting region Channel regulation
SAP97 100 C-terminus (PDZ domain) Trafﬁcking
Ankyrin-G 480 interdomain D2–3 linker
MOG1 20 interdomain D2–3 linker
Nav1.5 227 N-terminus
α-actinin-2 104 interdomain D3–4 linker
Calmodulin 56 C-terminus (IQ motif) and
interdomain D3–4
Desmoglein-2 122 Not determined Gating regulation
Plakophilin-2 97 Not determined
FGF proteins 28 C-terminus (aa 1773–1832)
14-3-3η 28 interdomain D1–2 linker
Caveolin-3 17 Not determined
GPD1-L 38 Not determined
Telethonin 19 Not determined
ZASP 77 Not determined
PTPH1 104 C-terminus (PDZ domain) Post-translational
modiﬁcationsNedd4-like
family
112 C-terminus (PY domain)
CAMKIIδc 56 Interdomain D1-2 linker
and via spectrina
Syntrophin 54 C-terminus (PDZ domain) Adaptation and stabilization
Table 3
Proteins implicated in Brugada syndrome and number of mutations identiﬁed.
Gene Protein No. of
mutations
described
(HGMD)
SCN5A Sodium channel, voltage gated, type V, alpha polypeptide 366
CACNA1C Calcium channel, voltage-dependent, l type, alpha 1c
subunit
10
TRPM4 Transient receptor potential cation channel, subfamily
M, member 4
9
CACNB2 Calcium channel, voltage-dependent, beta 2 subunit 7
KCNH2 Potassium voltage-gated channel, subfamily H,
member 2 (HERG)
6
CACNA2D1 Calcium channel, voltage-dependent, alpha 2/delta
subunit 1
4
HCN4 Hyperpolarization activated cyclic nucleotide-gated
potassium channel 4
3
SCN1bb Sodium channel, voltage-gated, type 1, beta, isoform b 3
ABCC9 ATP-binding cassette, sub-family C (CFTR/MRP),
member 9
3
KCND3 Potassium voltage-gated channel, Shal-related
subfamily, member 3
2
SCN3B Sodium channel, voltage-gated, type III, beta 2
SLMAP Sarcolemma associated protein 2
SCNN1A Sodium channel, non-voltage gated 1, alpha 2
SEMA3A Semaphorin-3A 2
CACNA1ct23 Calcium channel, voltage-dependent, l type, alpha 1c
subunit, transcript variant 23
1
CACNB2i5 Calcium channel, voltage-dependent, beta 2 subunit,
isoform 5
1
GPD1L Glycerol-3-phosphate dehydrogenase 1-like 1
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brane [33].KCNE3 Potassium voltage-gated channel, Isk-related family,
member 3
1
KCNJ8 Potassium inwardly-rectifying channel, subfamily J,
member 8
1
PKP2 Plakophilin 2 1
RANGRF RAN guanine nucleotide release factor 1
SCN2B Sodium channel, voltage-gated, type II, beta 1
KCNT1 Potassium channel, subfamily T, member 1 1
KCNJ16 Potassium inwardly-rectifying channel, subfamily J,
member 16
1
KCNB1 Potassium voltage-gated channel, Shab-related
subfamily, member 2
1
HGMD, Human Gene Mutation Database.7. Interacting proteins
TheNav1.5 protein is involved in a number of electrical (longQT syn-
drome [LQTS], Brugada syndrome [BrS], sick sinus syndrome [SSS], and
progressive cardiac conduction disease [PCCD]) and structural (dilated
cardiomyopathy [DCM]) cardiac diseases. The extensive pathologic
implications of Nav1.5 suggest that its function is linked to a complex
network of proteins. In fact, Nav1.5 interacts with several proteins
implicated in sodium current regulation, cellular trafﬁcking, and post-
transductional modiﬁcations (Table 1). The principal interacting region
is the cytosolic C-terminal tail that binds various proteins (syntrophin,
dystrophin, calmodulin, SAP97, nedd4-like, FGF13, and PTP-H1); the in-
tracellular interdomain linker loops are also implicated in these protein
interactions [34]. An interesting interactionwas thatwithα-actinin-2 at
the level of the ID3–4 that is implicated in the trafﬁcking of Nav1.5 to theTable 2
Cardiac disorders associated to Nav1.5 alterations.
Nav1.5-related disease Clinical features Gat
Long QT syndrome (LQTS) Ventricular tachyarrhythmias (TdP)
Ventricular ﬁbrillation
Syncope cardiac arrest
↑ pe
↑ ch
curr
Slow
Brugada syndrome (BrS) Ventricular arrhythmias
Sudden cardiac death
↓ in
Sick sinus syndrome (SSS) Sinus bradycardia
Sinus arrest/exit block
SA and AV nodal conductionDisturbances
Atrial tachyarrhythmias
↓ in
Progressive cardiac conduction
defects (PCCD)
Right and/or left bundle branch block
Complete atrioventricular block
Syncope sudden death
↓ in
Dilated cardiomyopathy (DCM) Structural defects arrhythmias and/or ﬁbrillationa Mix
↑ increasing; ↓ decreasing; TdP, torsade des pointes; SA, sinoatrial; AV, atrioventricular.
a In the presence of SCN5A mutations [71].plasma membrane, while biophysical properties of the channel were
not altered [35].
Other proteins are thought to beNav1.5 interactors, but their speciﬁc
interaction location has not yet been identiﬁed (Table 1). Two distinct
pools of Nav1.5 expression have been found at two different subcellularing alterations ECG alterations
rsistent Na current
annel availability ↑peak sodium
ent density
ed inactivation
QT-interval prolongation
ward Na current ST-segment elevation in (V1–V3)
↑ PQ- and QRS-duration (with normal QT interval)
ward Na current Slow heart rate
Irregular heart rhythm or pauses N2 s
Slow-fast alternation of heart rhythm
ward Na current QRS-widening
ed No unique ECG features
Biﬁd P wave
ST segment depression and T wave inversion
Left (or right) bundle branch block
Left axis deviationPremature ventricular complex
Ventricular bigeminy
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disk; a third pool at T-tubule level is hypothesized [34]. Each pool of
expression differs in their protein–protein interactions with Nav1.5. At
the lateral membrane pool, Nav1.5 interacts with the dystrophin/
syndtrophin multicomplex, (at the C-terminal tail) that is responsible
for sodium channel anchoring to the plasma membrane, which, in
turn, is required for correct channel function and expression at this
membrane, although protein SAP97 protein has been recently implicat-
ed in the expression sodium channel at the lateral membrane [36].
Instead, the pool of Nav1.5 at the intercalated disks interacts, in vivo,
with ankirin-G that is also linked with the desmosomal protein
plakophilin-2 [37]. Importantly, also the kinetic properties of the sodi-
um channel differed between the two Nav1.5 pools: compared with the
pool of Nav at the intercalated disk, the Nav1.5 at the lateral membrane
had a smaller current amplitude, a negative shift in the inactivation kinet-
ic and a slower recovery from inactivation [38]. The functions and impli-
cations of these distinct pools of expression in cardiac disorders are not
yet clear and remain an area of active investigation. A recent study
demonstrated interaction between two α-subunits in the endoplasmic
reticulum that is important for channel protein migration. In fact, this in-
teraction, involving N-terminus segments, directs the complex (two α-
subunits) to the plasma membrane. Mutations in the N-terminal tail of
an α-subunit causes a dominant negative effect that leads to BrS [39].
8. Channelopathies
The cardiac sodium channel is involved in several inherited diseases
collectively known as cardiac channelopathies (Table 2). These cardiac
disorders manifest with different electrocardiographic patterns and
sometimeswith different clinical features, although they are often char-
acterized by similar arrhythmic events. All can occur in subjects who do
not manifest clinical symptoms or a pathological phenotype but
they carry the genetic defect present in clinically affected relatives.
Speciﬁcally, mutations in the cardiac sodium channel-encoding gene
(SCN5A), which trigger biophysical alterations in the Nav1.5 protein,
are strictly related to the inherited cardiac channelopathies LQTS, BrS,
sick sinus syndrome (SSS) and progressive cardiac conduction disease
(PCCD). Genetic variations in SCN5A are also linked to other inherited
disorders characterized by structural alterations of the heart, namely,
DCM [40].
8.1. Long QT syndrome
LongQT syndrome is an inherited arrhythmic disorder characterized
by abnormal prolongation of the QT interval on the surface 12-lead ECG
in patients with a structurally normal heart [41]. Prolongation of the QT
interval is associated with delayed ventricular repolarization. The dis-
ease features polymorphic ventricular tachycardia (known as torsade
de pointes), syncope and sudden cardiac death [42]. Diagnosis is based
on a standard 12-lead ECG where the QT is measured and normalized
by heart rate (Bazett's formula: QTc = QT interval/√ RR), where RR is
the interval from the onset of one QRS complex to the onset of the
next QRS complex. LQTS is diagnosed in case of an LQTS Schwartz diag-
nostic score ≥3.5 in the absence of a secondary cause of QT interval pro-
longation; when genetic screening reveals an unequivocally pathogenic
mutation in an LQTS-related gene; and in case of QTc ≥500ms in repeat-
ed 12-lead ECG and without a secondary cause of QT interval prolonga-
tion. LQTS can be diagnosed also with a QTc ranging from 480 ms to
499ms (in repeated 12-lead ECG) in patientswith unexplained syncope
in the absence of secondary cause for prolongation of the QT interval
and of pathogenic mutations [43].
Heritable LQTS is classiﬁed in 13 subtypes (LQT1–LQT13) each of
which is linked to speciﬁc gene alteration. LQT1, LQT2 and LQT3 are the
most frequent genetic forms, and are related to mutations of cardiac ion
channel-encoding genes. LQT3 is associated with SCN5A mutations.
LQT3 patients show arrhythmia, and often, also bradycardia. Arrhythmicevents commonly occur during rest or sleep, unlike LQT1 and LQT2where
theymanifest during exercise (especially swimming) or emotional stress
(sudden noises like the ringing of an alarm clock), respectively [44].
Thousands of LQTS-related mutations have been identiﬁed in the 13
LQTS-associated genes, and many have been functionally characterized.
About 15% of all LQTS-causing mutations are in the SCN5A gene. They
are spread throughout the entire protein, and cause an increased in sodi-
um channel activity. LQT3 is triggered by gain-of-function mutations in
Nav1.5 that cause increased levels of the depolarizing sodium current
(INa). In fact, this surplus of inward depolarizing sodium current, during
phase 0 slows the repolarization phase, thus prolonging the CAP. The bio-
physical hallmark of LQT3 is increased levels of persistent sodium current
that are evoked by a disruption of the fast inactivation gate. LQT3-linked
mutations can also accelerate recovery from inactivation, disturb the
voltage-dependence of activation, and increase channel availability and
sodium current density [3].
Treatment of LQT3 with β-blockers (suggested with Class I consen-
sus recommendation in LQTS patients) may not be very effective, thus
a class Ib sodium channel blocker (mexiletine) is usually administered
as add-on therapy in these patients [45]. Recently, ranolazine, which
inhibits several ion currents, is now being administered as an antiar-
rhythmic drug for LQT3. This compound has two advantages. First,
in atrial cells it inhibits the peak INa, and second it inhibits the late
INa [46]. Thus, ranolazine can prevent atrial ﬁbrillation and LQT3.
Ranolazine inhibits also the IK and ICa,L currents, although it has been as-
sociated with mild side effects [46]. Consequently, long-term safety
monitoring is necessary before this treatment can be routinely applied
in the clinical setting [47]. Despite the advances made in the pharmaco-
logical treatment of LQT3, implantation of a cardioverter deﬁbrillator
(ICD) is currently the treatment of choice for high-risk patients [43].
8.2. Brugada syndrome
Brugada syndrome is an autosomal inherited channelopathy clini-
cally characterized by episodes of syncope, ventricular arrhythmia that
can lead to sudden cardiac death, often in apparently healthy young
subjects (≤40 years old) [48]. Symptoms usually appear in the third
decade of life and occur more often in men than women. These clinical
alterations appear in a structurally normal heart and usually occur dur-
ing rest or sleep [48]. In some BrS patients, fever unmasks the Brugada
ECG and also triggers fatal arrhythmias [49].
Diagnosis of BrS can be difﬁcult because the ECG changes are dynam-
ic and variable. Three ECG subtypes have been recognized: Type 1 BrS
features a coved-shaped ST elevation in right precordial leads (V1–V3)
with a J wave or ST elevation of ≥0.2 mV at its peak followed by a
negative T wave, with little or no isoelectric separation. Type 2 also
has a high take-off ST segment elevation, but the J wave amplitude
(≥0.2 mV) gives rise to a gradually descending ST-segment elevation
that remains ≥1 mV above baseline, followed by a positive or biphasic
T-wave that results in a saddleback conﬁguration. Type 3 features
right precordial ST elevation of b0.1 mV of the saddleback type or
coved type [50,51]. Based on these ECG features, BrS is diagnosed in pa-
tients with a type I morphology in ≥1 lead among the right precordial
leads V1, V2, occurring either spontaneously or challenge test with in-
travenous administration of Class I antiarrhythmic drugs, [43].
Loss-of-function mutations in the SCN5A gene, which reduce the INa
peak, or alter trafﬁcking, and result in the absence of the sodium chan-
nel in the plasmamembrane, have been related to BrS in approximately
10% to 30% of cases [52]. Patch-clamp analysis has demonstrated that
some SCN5Amutations impair cardiac sodium channel gating more se-
verely at higher temperatures, leading to further reduction in the INa
peak during fever and increasing arrhythmogenicity in BrS patients [53].
However, it remains to be established whether arrhythmias
arise consequent to altered repolarization, abnormal depolarization, or
both. The “repolarization hypothesis” is based on transmural dispersion
of repolarization between the endocardium and epicardium at the level
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ization hypothesis” is based on RV conduction slowing, caused by a con-
sistent reduction of the depolarizing current that is unable to initiate the
action potential, and on mild structural changes that may not become
evident with conventional cardiac imaging approaches [51].
Although SCN5A is the gene most often associated with the BrS
phenotype, other ion channels (CACNA1C and HERG) and/or accessory
subunit-encoding genes have been implicated in BrS [55]. The genes
associated with BrS are listed in Table 3.
Treatment of BrS patients is either pharmacological (e.g. isopro-
tenerol), radiofrequency catheter ablation or ICD implantation, which
is the only strategy able to prevent sudden cardiac death [43].
8.3. Sick sinus syndrome
Sick sinus syndrome is a cardiac disorder triggered by dysfunction of
the sinus atrial node (SAN) [56]. In SSS, the pacemaking function of SAN
is disrupted, which results in alteration of the normal cardiac impulse
conduction. Patientsmanifest a variety of ECG conditions: inappropriate
sinus bradycardia, sinus arrest or exit block, a combination of sinoatrial
and atrioventricular nodal conduction disturbances, and atrial tachyar-
rhythmias [57]. It can alsomanifest as the coexistence of atrial tachycar-
dia and bradycardia, in which cases is called tachycardia–bradycardia
syndrome. SSS occurs mainly in subjects older than 50 years, although
children can also be affected [56]. The symptoms of SSS can include cen-
tral nervous system alterations (e.g., syncope or pre-syncope) or cardio-
vascular alterations (e.g. angina pectoris) [57]. Other symptoms are
dizziness, errors in judgment, digestive disturbance. During exercise,
many affected individuals experience chest pain, difﬁculty in breathing,
or excessive tiredness (fatigue). Once symptoms of SSS appear, they
usually worsen with time. However, some people with the condition
never experience any related health problems [57].
SSS can result from genetic or environmental factors. In many cases,
the cause is unknown.More commonly, SSS is caused by factors that, in-
herently (e.g. idiopathic degenerative ﬁbrotic inﬁltration, amyloidosis
and cardiomyopathies) or extrinsically (e.g. hyperkalemia, hypoxia,
and pharmacologic agents), alter the structure or function of the SAN
[57]. In children SSS is attributed to congenital abnormalities or sinoatri-
al nodal artery deﬁciency [57].
Genetic changes are an uncommon cause of SSS. The condition is
usually inherited as an autosomal recessive trait associated, primarily,
with compound heterozygous mutations in the SCN5A gene. The reces-
sive inherited form of SSS includes double heterozygous mutations in
the SCN5A, LMNA A/C, EMD and GJA5 genes. The disorder may also be
associated to mutations in the HCN4 gene; this SSS form is inherited
as an autosomal dominant trait. Autosomal dominant inheritance of
SSS due to an SCN5A mutation has recently been reported [58].
The most typical biophysical feature of SSS-causative SCN5Amuta-
tions is the loss-of-function property that reduces electric coupling be-
tween the sinus node and surrounding atria that, in turn, results in
conduction block (exit block) [59]. However, some SCN5A gain-of-
function mutations cause SSS by prolonging the sinus node action po-
tential and disrupting its complete repolarization, which in turn, leads
to a reduction in sinus rate [60]. In case of severe SSS symptoms can
only be treated with permanent pacemaker implantation. In fact, phar-
macological treatment is not reliable [61].
8.4. Progressive cardiac conduction disease
Progressive cardiac conduction disease (PCCD) is an electric disorder
characterized dysfunctions of the conduction system. It is also called
Lev–Lenègre syndrome. The disorder affects the impulse propagation
through the His–Purkinje network and causes right/left bundle branch
block and enlargement of the ECG QRS complex. These electric alter-
ations can lead to syncope and sudden death. Deposition of ﬁbrous
tissue has been described in patients with conduction abnormalityin ventricles [62]. Pacemaker implantation is required to prevent
sudden death. Loss-of-function mutations, due to point mutations or
haploinsufﬁciency in the SCN5A gene, cause a reduction in the availabil-
ity of channels and are associated to PCCD [63,64]. In some cases, the
samemutation in the SCN5A gene can lead either to Brugada syndrome
or to an isolated cardiac conduction defect or to overlappingphenotypes
(e.g. LQTS and conduction defects) [65,66].
8.5. Inherited dilated cardiomyopathy
Dilated cardiomyopathy is a cardiac disorder characterized by dilata-
tion of the cardiac chambers and alteration of ventricle contractility
with a consequent reduction in systolic function. Symptomatic DCMpa-
tients can manifest heart failure, arrhythmias, and conduction defects
[67]. The causes of DCMare various and include coronary artery disease,
cardiotoxic drugs, and endocrine diseases; whereas, it is deﬁned idio-
pathic in 50%of cases. About 30%of idiopathic DCMpatients have a family
history of the condition, which suggests a familial form of the disorder
(FDCM). The condition is inherited as an autosomal dominant/recessive,
maternal, or X-linked trait [68], although autosomal dominant trans-
mission is the most frequent. More than 40 genes have been linked to
FDCM, most of which were identiﬁed in the cardiac z-disk or in sarco-
meric protein-encoding genes [69]. A recent study shows that 1.7% of
FDCM cases are associated with SCN5A mutations (point or truncation
mutations [70]) that are implicated in electrical excitability dysfunction.
Probably, altered excitability can lead to dilatation of the cardiac cham-
bers [71]. In fact, recent ﬁndings suggest that point mutations in VSD
(R222Q and R225W) generate gating pore currents leading to dilatation
of cardiac chambers [72]. An alternative DCM-causing mechanism is
cardiomyocyte acidiﬁcation induced by a mutation in SCN5A that
causes an H+ leak through the mutated channel [73].
9. Conclusions and perspectives
TheNav1.5 protein is located in the cellmembrane and is responsible
for the rapid upstroke of the CAP. It is implicated in several electrical and
structural cardiac diseases (LQTS, BrS, SSS, PCCD and DCM); in fact,
alteration of its biophysical behavior and its regulation are critical for
the onset of these diseases. Moreover, cardiac sodium channelopathies
manifest in different clinical phenotypes, and consequently require
different pharmacological therapies. Given the important role of this
protein in action potential generation and the complex network of
interacting proteins, Nav1.5 is probably involved in other cardiac
and non-cardiac diseases. Thus, the identiﬁcation of sodium channel
modulators and other genetic natural variants could shed light on
Nav1.5-related diseases and help to understand how alterations of this
protein can induce diverse clinical phenotypes. Considering that many
cardiac sodium channel disorders lead to sudden cardiac death, the
study of the biological and electrophysiological properties of Nav1.5,
coupled with genetic analysis of SCN5A and the modulator encoding
genes could enable risk stratiﬁcation in patients. In addition, the
demonstration of the modulator effect induced by sodium channel-
interacting proteins coupled with the electrophysiological characteriza-
tion of natural variants (in Nav1.5 and its interacting proteins) may be
helpful for genetic diagnosis and, probably, in the identiﬁcation of phar-
macological targets. Lastly, the recent unexpected ﬁnding that Nav1.5 is
implicated in the invasiveness of breast, colon, prostate, and lung cancer
cells [74,75] indicates that Nav1.5 plays various complex roles, some of
which are yet to be discovered.
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